The Science Behind it.

Novaerus NanoStrike Technology

Novaerus ultra-low energy patented plasma technology has been tested and proven to deactivate airborne bacteria and viruses, neutralise VOCs and reduce particulate such as mould spores, dust mites, pollen, and dander.

• Novaerus technology cleans the air 24/7. The portable air

dis-infection units are ideal for continuous infection control, odour mitigation and indoor air quality maintenance.

• Novaerus plasma is powerful, yet gentle. With no harmful

by-products, it is safe for continued use around vulnerable customers and staff, treating the air in real life conditions.

• Novaerus portable units are low-energy, low-maintenance and plug into any outlet. With no installation costs, the units can be easily moved by staff to the point of care.

Plasma_Coils_w_Plasma_Field.png
Plasma_Coil.jpg

Thermal plasma has been used for over 25 years in different sectors to clean and sterilise equipment and surfaces. The recent discovery of non-thermal plasma, operating at low temperature and consuming much less energy, has made it possible to generalise the use of plasma. Novaerus has taken this technology to the next level by applying it to air treatment, eliminating harmful microorganisms before they come into contact with residents, patients and healthcare staff.

Research

Utilizing NanoStrike Technology, Novaerus devices have been shown to safely and effectively reduce viruses, bacteria, mould spores, VOCs, and particulate matter in dozens of independent laboratory tests.

In case studies and clinical trials, our products have been demonstrated to reduce infections and improve wellbeing in real-world settings.

NV-Test-Results-Chart.jpg
New-banner-background-min (3).jpg
NanoStrike_Key_Outcomes_Table.jpg

Test Result Chart References 

  1. Tested on MS2 Bacteriophage, a surrogate for SARS-CoV-2 (2020 - Efficacy of the Novaerus NV1050 device against Aerosolized MS2 Virus, Aerosol Research and Engineering Laboratories)

  2. Tested on Human parainfluenza type 3 (HPIV3), a commonly used surrogate for Measles. (2019 – To assess the impact of an air purifier on Human parainfluenza virus Type 3,  Airmid Healthgroup)

  3. Tested on MS2 Bacteriophage, a surrogate for SARS-CoV-2 (2020 - Efficacy of the Novaerus NV1050 device against Aerosolized MS2 Virus, Aerosol Research and Engineering Laboratories)

  4. Tested on MS2 Bacteriophage, a surrogate for Norovirus (Tested on MS2 Bacteriophage, a commonly used surrogate for Norovirus (2005 - Survival of viruses on fresh produce, using MS2 as a surrogate for Norovirus, Dawson DJ et al.)

  5. Tested on MS2 Bacteriophage, a surrogate for Influenza (2010 – Evaluation of filters for the sampling and quantification of RNA Phage Aerosols, Louis Gendron et al.)

  6. Tested on Mycobacterium smegmatis, a commonly used surrogate for Mycobacterium tuberculosis (2007 - Evaluation of Mycobacterium smegmatis as a possible surrogate screen for selecting molecules active against multi-drug resistant Mycobacterium tuberculosis, Chaturvedi V et al.). 

  7. Tested on Staphylococcus epidermidis, a commonly used surrogate for MRSA. (2011 – Aerosol survival of Staphylococcus epidermidis, Thompson KA et al.)